<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03516591</url>
  </required_header>
  <id_info>
    <org_study_id>AMV564-201</org_study_id>
    <nct_id>NCT03516591</nct_id>
  </id_info>
  <brief_title>A Phase 1 Study of AMV564 in Patients With Intermediate or High-Risk Myelodysplastic Syndromes</brief_title>
  <official_title>A Phase 1, Multicenter, Open Label Study of AMV564, a Bispecific CD33/CD3 T-cell Engager, in Patients With Intermediate or High-Risk Myelodysplastic Syndromes</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Amphivena Therapeutics, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Amphivena Therapeutics, Inc.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      An open label, Phase 1, study of AMV564 as monotherapy to assess the safety and efficacy in
      patients with Myelodysplastic Syndromes
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      A dose-escalation with expansion study of AMV564 (T cell engager) as monotherapy in patients
      with intermediate-2 or high-risk Myelodysplastic Syndromes
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">May 2018</start_date>
  <completion_date type="Anticipated">July 2019</completion_date>
  <primary_completion_date type="Anticipated">March 2019</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Sequential Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Dose limiting toxicity (Dose Escalation)</measure>
    <time_frame>DLTs will be evaluated through 28 days</time_frame>
    <description>Dose limiting toxicity to be measured by AEs and SAEs by dose level</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Overall Response Rate (Dose Expansion)</measure>
    <time_frame>The treatment period will extend from initiation of AMV564 treatment until the Safety Follow Up visit (30 days after the end of infusion), or response assessment of the last induction cycle, whichever occurs later.</time_frame>
    <description>Overall response rate (ORR), defined as the proportion of patients who achieve a CR, marrow CR or PR by IWG criteria. Point estimates for ORR, along with the approximate lower 1-sided 90% confidence intervals, will be calculated.</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">56</enrollment>
  <condition>Myelodysplastic Syndrome (MDS)</condition>
  <arm_group>
    <arm_group_label>Dose Escalation (3+3 design)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>A 3 + 3 design, with dose-escalation of AMV564, up to a Maximum Tolerated Dose (MTD) level</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Dose Expansion</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Following determination of the MTD of AMV564, the study will expand at the MTD or a dose level lower than the MTD to obtain initial estimates of response rates and additional information on safety.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>AMV564</intervention_name>
    <description>Two dosing regimens, a 7-day and a 14 day AMV564 continuous intravenous infusion regimen</description>
    <arm_group_label>Dose Escalation (3+3 design)</arm_group_label>
    <arm_group_label>Dose Expansion</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  ≥ 18 years of age

          -  Diagnosis of MDS according to WHO 2016 criteria

          -  ECOG performance status of 0 or 1

          -  Intermediate-2 or high-risk disease per IPSS

          -  Fewer than 20% blasts in the bone marrow or peripheral blood

          -  Disease that is refractory to or relapsed from either a hypomethylating agent (e.g.
             decitabine or azacitidine) or a standard AML-type intensive regimen

          -  Adequate organ function

          -  Prior allogeneic transplant performed ≥ 6 months prior to first dose of AMV564 is
             allowed provided there is no evidence of active graft-versus-host disease (GVHD) and
             the patient has been off immunosuppressive therapy for ≥ 4 weeks.

        Exclusion Criteria:

          -  History of, or known, central nervous system (CNS) disease involvement, or prior
             history of National Cancer Institute (NCI) Common Toxicity Criteria for Adverse Events
             (CTCAE) Grade ≥ 3 drug-related CNS toxicity

          -  Prior allogeneic transplant if performed &lt; 6 months prior to first dose of AMV564, if
             patient has active GVHD, or if patient has not been off immunosuppressive

          -  Prior treatment with a therapeutic agent targeting CD33 and/or CD3 (e.g. gemtuzumab
             ozogamicin, SGN-CD33A or AMG 330).
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Eric Feldman, MD</last_name>
    <role>Study Director</role>
    <affiliation>Amphivena Therapeutics, Inc.</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Laura Szewczyk</last_name>
    <phone>1-833-AMPHITX (267-4489)</phone>
    <email>clinical@amphivena.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Sascha Ellers</last_name>
    <phone>1-833-AMPHITX (267-4489)</phone>
    <email>clinical@amphivena.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>MD Anderson</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Baily Mirabella, RN, BSN</last_name>
      <phone>713-563-0708</phone>
      <email>BLMirabella@mdanderson.org</email>
    </contact>
    <investigator>
      <last_name>Guillermo Garcia-Manero, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>May 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>April 24, 2018</study_first_submitted>
  <study_first_submitted_qc>April 24, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">May 4, 2018</study_first_posted>
  <last_update_submitted>May 21, 2018</last_update_submitted>
  <last_update_submitted_qc>May 21, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">May 22, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Syndrome</mesh_term>
    <mesh_term>Myelodysplastic Syndromes</mesh_term>
    <mesh_term>Preleukemia</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

